Table 3.
Clinical outcome of each patient
| Patient no. | Efficacy at 2 W | PSL tapering (mg/day) | Long-term (1 Y) outcome | Adverse events | |
|---|---|---|---|---|---|
| Prior | at 24 W | ||||
| 1 | Yes | 25 | 5 | In remission at 1 Y | None |
| 2 | Yes | 40 | 3 | In remission at 1 Y | None |
| 3 | Yes | 60 | 2.5 | In remission at 1 Y | None |
| 4 | Yes | 0 | – | Resistance to IFX | Transient high fever |
| 5 | Yes | 60 | 0 | Relapse after 9 M | None |
| 6 | No | 40 | – | Colectomy after induction of remission with AM | None |
| 7 | Yes | 30 | 5 | Relapse after 12 M | None |
Y year, M month, W week, PSL prednisolone, IFX infliximab, AM adrenomedullin